Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alustal
- Development stage
- Phase 4
- Lead developer
- Stallergenes Greer
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Alustal is an allergen immunotherapy (AIT) product developed and marketed by Stallergenes Greer. It consists of allergen extracts (such as pollen, dust mites, or molds) adsorbed onto an aluminum hydroxide adjuvant, formulated as a suspension for subcutaneous injection (SCIT). Alustal is indicated for the treatment of Type I allergic diseases, including seasonal or perennial allergic rhinitis, conjunctivitis, and mild to moderate asthma in adults and children aged five and older. The mechanism of action involves the slow release of allergens from the aluminum adjuvant at the injection site, which facilitates the induction of clinical and immunological tolerance. This process modulates the immune system by shifting the response from a Th2-dominated allergic profile toward a Th1 and regulatory T-cell (Treg) response, ultimately reducing the production of allergen-specific IgE and decreasing inflammatory symptoms upon subsequent allergen exposure.
- Brand names
- Alustal
- Other names
- Alustal Rapid
02
Targets
MHC II (Major histocompatibility complex class II receptor)IgE (Immunoglobulin E)γδ TCR (T-cell receptor)
Beyond the preview
Go deeper on Alustal.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alustal.